Oncovir, Inc. is focused on the development of Hiltonol® (Poly ICLC), a synthetic double-stranded RNA (dsRNA) viral mimic that serves as both an immunotherapy drug and a vaccine adjuvant for cancer and infectious diseases. Hiltonol® activates both innate and adaptive immunity, leveraging the body's natural defense mechanisms to enhance immune responses. Its mechanisms of action include promoting the expression of tumor antigens and neoantigens, inducing natural killer (NK) cells, and activating various immune pathways through Toll-like receptor 3 (TLR3) and MDA5. This multifaceted approach positions Hiltonol® as a critical component in cancer immunotherapy, particularly in overcoming immune suppression within the tumor microenvironment.

The biological effects of Hiltonol® extend beyond cancer treatment, as it also exhibits antiviral properties and supports the activation of immunological memory. By enhancing the activity of immune cells such as dendritic cells, T-cells, and B cells, Hiltonol® facilitates a robust immune response characterized by the production of interferons, cytokines, and chemokines. Its formulation, which includes poly-L-lysine and carboxymethylcellulose, stabilizes the dsRNA structure, allowing for effective immune modulation. Overall, Hiltonol® represents a promising therapeutic strategy for enhancing the efficacy of cancer vaccines and improving patient outcomes in oncology and infectious disease contexts.

United States

Oncovir, Inc is a pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders.

We promote Hiltonol® (poly-ICLC) as an experimental viral mimic and broad activator of innate and adaptive immunity. While initially developed as an interferon inducer, Hiltonol® has much broader biological effects in humans, including specific antiviral, immune activating, vaccine adjuvant, and antitumor actions. 

Oncovir

Company Details